News | October 29, 2013

Biotronik Japan Announces First Patients Enrolled in Bioflow-IV Clinical Study

Bioflow-IV aims to compare Orsiro Hybrid Drug-Eluting Stent to Abbott's Xience Prime/Xpedition

biotronik orsiro stents drug-eluting cinical trial bioflow
October 29, 2013 — Biotronik Japan announced enrollment of the first patient in the Bioflow-IV study, which aims to verify the efficacy and safety of the Orsiro Hybrid Drug-Eluting Stent (DES) from Biotronik. The quality and efficacy of Orsiro has already been confirmed by the trials Bioflow-I, -II and -III, which demonstrated the safety and efficacy of Orsiro.??
The Bioflow-IV study is the first prospective, randomized, controlled, global study to compare the target vessel failure (TVF) rate of Orsiro DES and Abbott Vascular’s Xience Prime/Xpedition DES in a non-inferiority setting. Twelve sites in Japan and 29 sites in the European Union are participating in the multi-center study with the primary endpoint of TVF at 12 months.??
Coordinating investigator of the Bioflow-IV study, Shigeru Saito, M.D., director, Cardiology and Catheterization Laboratories, and vice president, Shonan Kamakura Hospital, Kanagawa, Japan, implanted the first stent in the study. 
"Orsiro has excellent deliverability and obviously thinner struts by IVUS observation than the current available DESs in Japan, which would be associated with earlier neointimal coverage after Orsiro implantation," said Saito.
Efficacy and safety of Orsiro as demonstrated by the BIOFLOW-I, - II, and -III studies:?
In the Bioflow-I first in-man study, late lumen loss, which was the primary endpoint, was 0.05±0.22 mm at nine months.??
Presented at EuroPCR 2013, Bioflow-II was a prospective, non-inferiority randomized controlled study comparing Orsiro with Xience Prime. The primary endpoint in-stent late lumen loss at nine months verified non-inferiority, which was confirmed with 0.10±0.32mm versus 0.11±0.29mm, respectively. There was also no significant difference in target lesion failure (TLF) at nine months, which was 4.8 percent in the Orsiro arm versus 5.3 percent in the Xience arm.?
As a prospective, all-comers, multi-center registry, Bioflow-III’s primary endpoint demonstrated 4.7 percent of TLF at 12 months.?
For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Clinical Study | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init